SII boosts cervical cancer shots supply ahead of govt mass drive

Poonawalla expects the vaccine to be "substantially, probably eight times, cheaper" when supplied to the government.;

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2024-03-04 09:13 GMT | Update On 2024-03-20 11:01 GMT

Pune: Serum Institute of India aims to significantly boost supply of its human papillomavirus (HPV) vaccine as it gears up to provide its shots to the government at cheaper rates for an immunisation campaign this year against the cancer-causing virus.

Adar Poonawalla, the CEO of the world's biggest vaccine maker by the number of doses, told Reuters that he expects the vaccine to be a part of the government's programme by year-end.

The vaccine, currently available in the private market for 2,000 rupees ($24.13), is India's first indigenous shot against HPV that plays a role in causing most cervical cancers in the world.

"Our capacity at the moment is just a few million doses but the demand is infinite. If we were to roll out 50 million doses in India, they would be used up, both in the private market and the government procurement scheme," said Poonawalla.

The government is set to administer the HPV vaccine to girls aged between nine and 14 years as part of a campaign to fight cervical cancer, the second-most common type of cancer in women in India.

There is no contract yet with the government, Poonawalla said, adding that he expects the authorities to initially procure between 40 to 50 million doses through a tender process in December.

Other HPV vaccine makers include Merck & Co. and GSK Plc. , who could also bid for government contracts.

"It's still a bit early to say but we're just poised and very committed to this product," he said.

Poonawalla expects the vaccine to be "substantially, probably eight times, cheaper" when supplied to the government.

Serum produces AstraZeneca's COVID-19 vaccine under the brand name Covishield in India.

The company's HPV facilities, which were used during the pandemic to manufacture Covishield are still not entirely operational, restraining full capacity, according to Serum.

The company is in the process of applying for WHO's pre-qualification and Poonawalla expects to begin exporting the HPV shots to other countries in 2026.

Original news source: https://www.reuters.com/business/healthcare-pharmaceuticals/indias-serum-boosts-supply-cervical-cancer-shots-ahead-governments-mass-drive-2024-03-03/#:~:text=PUNE, March 4 (Reuters),against the cancer-causing virus.

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

SII boosts cervical cancer shots supply ahead of govt mass drive

Poonawalla expects the vaccine to be "substantially, probably eight times, cheaper" when supplied to the government.;

Similar News

CDSCO Criminal Prosecution Against IndiaMART Put on Hold by Delhi HC Till Sept 17

Novo Nordisk Gets CDSCO Panel Nod for Rybelsus Label Update, Aligned with EMA

NPPA Updates Ceiling Price Applicability for Ringer Lactate Non-Glass Packs, Details

CDSCO Eases Rules for Biopharma Research, Will Accept Lab Biosafety Committee Approvals

41 Pharmacies in Delhi Caught Illegally Selling Abortion Pills Mifepristone, Misoprostol

Visakhapatnam Pharma Plant Gas Leak Claims Chemist's Life, CITU Alleges Negligence

Torrent Pharma to acquire 26% stake in Torrent Urja 27 for captive renewable power project

Sanofi Tzield approved in China for adult, pediatric patients with stage 2 type 1 diabetes